Cumulative impact of 10 common genetic variants on colorectal cancer risk in 42,333 individuals from eight populations by Dunlop, Malcolm et al.
 
 
 
 
 
 
 
 
 
 
 
 
 
This is an author produced version of a paper published in 
Gut. This paper has been peer-reviewed but does not include 
the final publisher proof-corrections or journal pagination. 
 
Pubmed citation for the paper: 
 
Gut. 2012 May 22. [Epub ahead of print] 
 
Cumulative impact of common genetic variants and 
other risk factors on colorectal cancer risk in 42 103 
individuals. 
 
Dunlop MG, Tenesa A, Farrington SM, Ballereau S, 
Brewster DH, Koessler T, Pharoah P, Schafmayer C, 
Hampe J, Völzke H, Chang-Claude J, Hoffmeister M, 
Brenner H, von Holst S, Picelli S, Lindblom A, Jenkins 
MA, Hopper JL, Casey G, Duggan D, Newcomb PA, Abulí 
A, Bessa X, Ruiz-Ponte C, Castellví-Bel S, Niittymäki I, 
Tuupanen S, Karhu A, Aaltonen L, Zanke B, Hudson T, 
Gallinger S, Barclay E, Martin L, Gorman M, Carvajal-
Carmona L, Walther A, Kerr D, Lubbe S, Broderick P, 
Chandler I, Pittman A, Penegar S, Campbell H, 
Tomlinson I, Houlston RS. 
 
URL: http://dx.doi.org/10.1136/gutjnl-2011-300537 
 
Access to the published version may require subscription. 
Published with permission from: BMJ Group 
Cumulative impact of 10 common genetic variants on colorectal cancer 
risk in 42,333 individuals from eight populations. 
 
 
1Malcolm G Dunlop§*, 1Albert Tenesa*, 1Susan M Farrington, 1Marion Walker, 1,2Evropi 
Theodoratou, 1James G Prendergast, 1Rebecca A Barnetson, 3Nicola Cartwright, 
4Roseanne Cetnarskyj, 1David H Brewster, 3Mary E Porteous, 5Thibaud Kossler, 5Paul 
DP Pharoah, 6, 7Clemens Schafmayer, 7Dieter Bröring, 8Stefan Schreiber, 8Stephan 
Buch, 8Jochen Hampe, 9Henry Völzke, 10Jenny Chang-Claude, 10Michael Hoffmeister, 
10Hermann Brenner, 11Susanna von Holst, 11Simone Picelli, 11Annika Lindblom, 
Swedish Low-Risk Colorectal Cancer Study Group, 12Mark A. Jenkins, 12John L Hopper, 
13Dan Buchanan, 13Joanne Young, 14Christopher K Edlund, 14David V Conti, 14Graham 
Casey, 15David Duggan, 16Polly Newcomb, 17Anna Abulí, 17Xavier Bessa, 17Montserrat 
Andreu, 18Ceres Fernández-Rozadilla, 18Angel Carracedo, 18Clara Ruiz-Ponte, 19Victoria 
Gonzalo, 19Antoni Castells, 19Sergi Castellví-Bel, 20EPICOLON consortium, 21Iina 
Niittymäki, 21Sari Tuupanen, 21Auli Karhu, 21Lauri Aaltonen, 22,23,24Brent W Zanke, 
22,25,26Celia MT Greenwood, 25Jagadish Rangrej, 22Rafal Kustra, 27Alexandre Montpetit, 
22, 23,28Thomas J Hudson, 22, 29Steven Gallinger, 30Ella Barclay, 30Lynn Martin, 30Maggie 
Gorman, 30Luis Carvajal-Carmona, 30Sarah Spain, 30Zoe Kemp, 30Kimberley Howarth, 
30Enric Domingo, 30Axel Walther, CORGI Consortium, 30Jean-Baptiste Cazier, 31Rachel 
Mager, 31Elaine Johnstone, 31Rachel Midgely, 31David Kerr, 32Steven Lubbe, 32Peter 
Broderick, 32Ian Chandler, 32Alan Pittman, 32Steven Penegar, COGENT consortium, 1, 
2Harry CampbellS, 30Ian TomlinsonS, 32Richard S HoulstonS. 
 
*Joint first authors.  
 
SJoint authors at this position.  
 
 
 
§Corresponding Author 
Malcolm Dunlop 
Colon Cancer Genetics Group, Institute of Genetics and Molecular Medicine, University of 
Edinburgh and MRC Human Genetics Unit, Edinburgh EH4 2XU.  
Tel: +44-(0)131 467-8454  Fax: +44-(0)131 467-8450 
Malcolm.Dunlop@hgu.mrc.ac.uk 
 
 1
Affiliations 
 
1. Colon Cancer Genetics Group, Institute of Genetics and Molecular Medicine, 
University of Edinburgh and MRC Human Genetics Unit, Edinburgh EH4 2XU.  
2. Public Health Sciences, University of Edinburgh, Teviot Place, Edinburgh EH8 9AG, 
UK  
3. Southeast of Scotland Clinical Genetic Services, Western General Hospital, Crewe 
Rd, Edinburgh, EH4 2XU, UK  
4. School of Nursing, Midwifery & Social Care, Faculty of Health, Life and Social 
Sciences, Napier University, Edinburgh, UK. 
5. Cancer Research UK Laboratories, Department of Oncology, University of 
Cambridge, Cambridge CB1 8RN 
6. POPGEN Biobank, University Hospital Schleswig-Holstein, Campus Kiel, 
Schittenhelmstrasse 12, Kiel 24105, Germany. 
7. Department of General and Thoracic Surgery, University Hospital Schleswig-
Holstein, Campus Kiel, Arnold-Heller-Strasse 3, Kiel 24105, Germany 
8. Department of General Internal Medicine, University Hospital, Schleswig-Holstein, 
Campus Kiel, Arnold-Heller-Straße 3 (Haus 6, Nebengebäude Haus 5), Kiel 24105, 
Germany. 
9. Institut fuer Community Medicine, University Hospital Greifswald, Walther-
Rathenau-Strasse 48, Greifswald 17487, Germany. 
10. Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Im 
Neuenheimer Feld 280, 69120 Heidelberg (JC-C) and Division of Clinical Epidemiology 
and Aging Research, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 
280, 69120 Heidelberg, Germany (MH, HB). 
11. Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, 
Sweden. 
12. Centre for Molecular, Environmental, Genetic and Analytic Epidemiology, The 
University of Melbourne, Parkville, Victoria, Australia. 
13. Familial Cancer Laboratory, Queensland Institute of Medical Research, Brisbane, 
Queensland, Australia.  
14. Department of Preventive Medicine, Keck School of Medicine, University of 
Southern California, Los Angeles, California, USA. 
15. Translational Genomics Research Institute (TGen), Phoenix, Arizona, USA. 
16. Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue N., Seattle, WA  
98109–1024. USA. 
17. Department of Gastroenterology, Hospital del Mar, Institut Municipal 
d'Investigació Mèdica (IMIM), Pompeu Fabra University, Barcelona, Catalonia, Spain. 
18. Fundación Pública Galega de Medicina Xenómica (FPGMX), CIBERER, Genomic 
Medicine Group - University of Santiago de Compostela, Santiago de Compostela, 
Galicia, Spain.  
19. Department of Gastroenterology, Hospital Clínic, CIBERehd, IDIBAPS, University 
of Barcelona, Catalonia, Spain.  
20. Gastrointestinal Oncology Group of the Spanish Gastroenterological Association.  
21. Department of Medical Genetics, Biomedicum Helsinki, University of Helsinki, 
Helsinki, Finland. 
22. Cancer Care Ontario, 620 University Ave. Toronto Ontario M5G 1L7, Canada.  
23. Ontario Institute for Cancer Research, Toronto, ON M5G 0A3, Canada.  
24. University of Ottawa, Faculty of Medicine, Division of Hematology, 501 Smythe 
Rd. Ottawa, Canada K1H 8L6.  
25. Genetics and Genome Biology, Hospital for Sick Children, 15-703 TMDT East, 101 
College Street, Toronto, ON M5G 1L7 555 Canada.  
26. University of Toronto, Department of Public Health Sciences Health Sciences 
Building, 155 College Street, Toronto, M5T 3M7, Canada.  
 2
27. The McGill University and Genome Quebec Innovation Centre. 700 Dr. Penfield 
Ave. Montreal Quebec, H3G 1A4, Canada.  
28. University of Toronto, Departments of Medical Biophysics and Molecular Genetics, 
Toronto, ON, Canada. 
29. Samuel Lunenfeld Research Institute, Mount Sinai Hospital and University of 
Toronto, 600 University Ave. Toronto Ontario M5G 1X5, Canada. 
30. Wellcome Trust Centre for Human Genetics, Roosevelt Drive, Oxford OX3 7BN, 
UK. 
31. Department of Clinical Pharmacology, Oxford University, Radcliffe Infirmary, 
Oxford, OX2 6HA, UK. 
32. Section of Cancer Genetics, Institute of Cancer Research, Sutton, Surrey SM2 
5NG, UK. 
 3
Abstract 
 
Background 
Stratification of colorectal cancer (CRC) risk within the population offers potential to 
refine surveillance guidelines and inform preventative interventions. Recent 
discoveries have shown that 10 common genetic susceptibility variants individually 
influence CRC risk. We investigated the utility of genetic risk profiling in 42,333 
subjects from eight populations of European descent. 
 
Methods 
Binary logistic regression was used to assess the effects of age, gender, family history 
(FH) and genotypes at all 10 CRC susceptibility loci. Risk models were generated by 
incorporating genotypes alone (n=39,266), or in combination with gender, age and FH 
(n=11,324). Discriminatory performance was assessed by generating ROC curves 
from 10-fold internal cross-validation and an independent case-control set (n=3,067). 
10-year absolute risk was estimated by modelling genotype and FH with age- and 
gender-specific population risk. 
 
Findings 
There was a highly significant difference in mean and median number of risk alleles in 
cases compared to controls (median in cases = 10 alleles vs. 9 in controls, p<2.2 x 
10-16). However, model discriminative performance across the risk spectrum was 
limited for genotypes alone (area under curve (AUC) 0.57) or incorporating genotype, 
age, gender, FH (AUC 0.59). Genotyping of an external case/control set validated the 
association between number of risk alleles and CRC risk (p=1.2x10-6). Mean per-allele 
increase in risk was 9% (OR 1.09; 95% CI 1.05-1.13). Modelling genotype, FH, age, 
gender with population risk enabled identification of a population subgroup (4 per 
1000) with a predicted 10-year absolute risk of CRC greater than 5%. 
 
Interpretation 
This study demonstrates that population subgroups can be identified with a predicted 
absolute CRC risk sufficiently high as to merit surveillance/intervention, although 
individualized CRC risk profiling is not currently feasible. Nonetheless, the findings 
provide the first tangible evidence of public health relevance for data from genome-
wide studies in CRC. 
 
Funding 
Multiple charitable and government grants. 
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Introduction 
 
Colorectal cancer (CRC) is one of the most common cancers in Western countries1. 
Although there is a 25-fold variation in CRC incidence worldwide, this is rapidly 
narrowing due to increasing exposure to “westernised” lifestyle risk factors in 
countries with historically low rates. Thus, incidence projections indicate that the 
death toll is set to rise substantially over the next decade. Already the global annual 
incidence exceeds 1 million cases, accounting for ~9% of all cancer cases1. The 
lifetime risk of developing the disease is ~5% in high incidence populations such as 
the UK (http://info.cancerresearchuk.org/cancerstats).  
 
Despite substantial progress made over the last twenty years, CRC remains a common 
cause of cancer death and suffering. Population-based registry data indicate that 
overall survival from CRC typically remains at only ~50%2. Furthermore, even when 
cure is attainable, there is appreciable morbidity associated with surgery and adjuvant 
therapies. Population-based screening has been introduced in many countries to 
identify prevalent disease at an early, curable stage. However, population screening 
modalities such as faecal occult blood (FOB) testing have only modest sensitivity. 
Nonetheless, early detection by screening average risk populations has been shown to 
shift detection to earlier stage disease, with resultant mortality reductions3. Incidence 
reduction is also achievable through colonoscopic polypectomy, both in the general 
population4,5 and in genetically defined high risk groups6,7. Thus, identifying population 
subgroups with an increased CRC risk offers the potential of tailoring colorectal 
surveillance intensity to predicted level of risk. 
 
Twin studies show that inherited predisposition contributes ~35% of trait variance for 
CRC8.  However, only around 5% of cases are attributable to highly-penetrant 
mutations such as DNA mismatch repair defects responsible for Lynch Syndrome or 
APC mutations that cause familial adenomatous polyposis. Recent genome-wide 
association studies have identified 10 risk loci for CRC9-16, thereby confirming the 
hypothesis that an appreciable component of the excess familial risk is a consequence 
of common genetic variants.  
 
Risk associated with each of the 10 loci is individually modest, but the impact on CRC 
incidence is significant because of the high population frequency of risk alleles. 
Moreover, high absolute risks could be apparent in a subset of the population who 
carry multiple risk alleles. Whilst the impact of these new discoveries on the clinical 
management of most individuals may be limited, application of genotype data offers 
the possibility of identifying a population subgroup with genetic risk that exceeds a 
predetermined absolute risk threshold triggering clinical intervention. Indeed, it is 
already established clinical practice to offer colonoscopic surveillance to those with a 
relatively modest excess risk due to a history of CRC 5, as well as to mutation carriers 
from Lynch Syndrome families who have a more substantial increase in CRC risk 17-19. 
This is an attractive approach because more intensive surveillance may be indicated 
for those at highest risk, whilst those who do not reach a predetermined threshold 
need only be offered screening for average risk individuals, as has been proposed for 
breast cancer20. 
 
We set out to determine the utility of 10 common genetic variants for (i) profiling the 
genetic risk of CRC in the population and (ii) identifying population subgroups with 
sufficiently high risk to merit additional, more intensive or earlier colonic surveillance. 
We developed and tested models using age, gender, family history and genotype data 
from up to 42,333 individuals from eight populations of European descent.  
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Methods 
Study subjects 
To generate the risk models, we initially studied a total of 44,389 subjects (24,395 
CRC cases, 19,994 cancer-free controls) from seven geographically distinct 
populations, predominantly of European origin. Blood sample collection, along with 
collection of age, gender demographic and clinical data from these cases and controls 
was undertaken with informed consent and ethical review board approval in 
accordance with the tenets of the Declaration of Helsinki. The samples sets used to 
generate the models comprised UK- (COGS and SOCCS studies), UK – (CORGI and 
NSCCG studies), UK – VICTOR study; UK - East Anglia (SEARCH); Canada - Ontario 
(ARCTIC); Spain (EPICOLON1 and EPICOLON2); Melbourne, Seattle (Colon CFR), 
Germany – Heidelberg and Kiel (DACHS and POPGEN). In addition, we genotyped 
3,067 subjects (1563 cases and 1504 controls) from Sweden and used data from all 
10 SNPs as an external validation. Thus, a total of 47,917 subjects were included in 
this study and sample numbers from each population are presented in Table 1 along 
with the nature and source of case and control subjects. Family history information 
was available for a subset of study subjects. Study populations with available family 
history data (with limited or no selection bias on the basis of family history) are 
detailed in Table 2. Family history of CRC was considered as a categorical variable, 
dependent on the presence or absence of at least one first degree relative affected by 
CRC at any age at the time of recruitment to the respective study. 
Genotyping 
DNA purification and quality control are described elsewhere14,16. Genotyping was 
performed using a variety of different platforms currently in use at each of the 
contributing sites. This included Illumina HumanHap550, Illumina HumanHap300 and 
240S, Illumina iSelect, competitive allele-specific PCR KASPar chemistry 
(KBiosciences), Taqman (Applied Biosystems), single-base primer extension chemistry 
matrix-assisted laser desorption ionization time of flight mass spectrometry (MALDI-
TOF MS) detection (Sequenom). Primers and probes are all available on request. 
Appropriate genotyping quality control procedures were in place in each centre, to 
ensure reproducible results, including genotyping duplicate DNA samples within 
studies and SNP assays and direct sequencing of subsets of samples to confirm 
genotyping accuracy. SNPs (chromosomal locations) shown previously to be 
associated with CRC risk are: rs6983267 (chr 8q24)9-11,16, rs4779584 (chr 15q23)13, 
rs4939827 (chr 18q21)12,14, rs3802842(chr 11q23)14,15, rs10795668 (chr 10p14)14,15, 
rs16892766 (chr 8q23)14,15, rs4444235(chr 14q22)16, rs9929218 (chr 16q22)16, 
rs10411210 (chr 19q13)16, rs961253 (chr 20p12)16.  
Statistical analysis 
Allele counts were performed in cases and controls for each of the 10 CRC SNPs (as 
above) and allele frequencies calculated for each population. The effects of SNP 
genotype, gender and family history were assessed using binary logistic regression. 
The total number of risk alleles for each population, and for all samples from the 
model generation set together, was then assessed and a two-sided t-test applied to 
compare the mean number of risk alleles between cases and controls.  
Risk modelling  
Due to missing values in each of the studies, generation and internal validation of the 
risk model was based on up to 39,266 samples because subjects were required to 
have complete data for all 10 SNPs. The probability that a person carrying a given 
number of common risk alleles develops CRC by a particular age was estimated using 
a Bayesian approach. Probability by age x is expressed as P(Dx). To estimate the 
probability that carriers of ≥Z alleles (G=1) develop CRC by a given age, then 
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. 
The probability that a person with < Z risk alleles develops CRC by a given age x is  
 
We assume that P(G=1|Dx) and P(G=0|Dx) are the same for all x and call these 
P(G=1|D and P(G=0|D)). This is reasonable given that each allele exerts a constant 
effect on risk throughout measurable human lifespan 14,16. P(G=1|D) and P(G=0|D) 
can be estimated from the data as the frequency of patients with ≥Z or <Z risk 
alleles, respectively. P(G=1) and P(G=0) were also estimated from control data to 
gauge the “carrier” frequency of high risk alleles in the general population. We 
recognise that some control sets were enriched for cancer-free status at the time of 
sampling and so this may marginally under-represent P(G=1) in the general 
population. 
Multivariate analysis using binary logistic regression was conducted to test the effect of 
each SNP allele and each covariate. Depending on study population grouping, the model 
included: genotype data from 10 SNPs - rs10411210, rs9929218, rs6983267, 
rs4779584, rs4939827, rs3802842, rs10795668, rs16892766, rs961253, rs4444235; 
family history status; age; gender. Age was included as a continuous variable. An 
additive model was assumed for each SNP.  
Assessment of risk model performance  
Risk model performance was assessed by rigorous internal, and external, validation. A 
10-fold cross-validation approach and subsequently using a external case/control set 
from Sweden. Initially, 10-fold cross-validation was used to estimate receiver operator 
characteristic (ROC) curves. This consisted of random assignation of study subjects 
and all associated data for that individual into 10 complementary datasets. One 
dataset at a time was then used as the validation set and the remaining 9 datasets as 
the training set. The statistical package ‘ROCR’ was used for the 10-fold cross-
validation21. Separate ROC curves were generated for models incorporating: (i) age, 
gender, family history and genotypes at all 10 loci for the population-based non FH-
selected study populations (Table 2); (ii) 10 locus genotypes for all datasets. Next, an 
external validation was conducted using an independent case/control set from 
Sweden. The model fitted in the analysis using all 10 SNP genotypes described above 
was evaluated in 1,563 Swedish cases and 1,504 controls and ROC curves were 
generated. We estimated the probability of a subject being a case or control and 
estimated the proportion of true and false positives at different cut-off points. 
Determination of absolute risk 
In view of comprehensive population coverage and high levels of completeness22, we 
used Scottish population and Cancer Registry data as reference for estimation of the 
probability of developing CRC in the population. We consider this to be a valid 
assumption because CRC incidence in Scotland is broadly representative of the 
northern European populations from which case and control sample sets were drawn2. 
Age-specific CRC rate was calculated from 2006 cancer registration data and from 
age-specific estimates of the Scottish population in that year 
(http://www.isdscotland.org/isd/3535.html). The cumulative CRC rate for any given age was 
calculated separately for males and for females as the sum of the age-specific rates 
up to that age. The cumulative probability was estimated from 1-exp(-cumulative 
rate) and the absolute risk in the next 10 years obtained by subtraction of the 
estimated cumulative risk up to the current age from the estimated cumulative risk 
for 10 years older than the current age. The cumulative probability of developing CRC 
in the general population by various ages is shown in supplementary Table 3 along 
with absolute risks in the general population and also by FH status and by genotype. 
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Results 
The distribution of risk allele frequency in all study populations combined is shown in 
Figure 1 and comparisons between populations as a box plot in Figure 2. For clarity in 
Figure 1, odds ratios (95% CI) are shown for subjects carrying 4 or less risk alleles as 
a group, and 14 or more as a group because of the very small numbers of subjects at 
these extremes. At the high-risk tail of the distribution curve in the combined sample 
sets, the frequency of carriage of >12, >13 and >14 alleles (equating to 
P(G=1|D)=1-P(G=0|D)) was respectively 0.205 0.091 and 0.032. Thus, 
approximately 20% of CRC cases carried 12 or more risk alleles. The frequency in 
control subjects is the most relevant to instigating preventative measures in the 
general population and 14.1%, 5.5% and 1.7% respectively carried >12, >13 and 
>14 alleles (equating to P(G=1)) in this group.  
There was a highly significant difference in mean number of risk alleles between cases 
and controls (2-sided t-test. p = 2.2 x 10-16). The mean number of risk alleles in 
control subjects was 9.39 compared to 9.93 in cases (difference - 0.53 alleles, 95% CI 
0.57-0.49) and median number of alleles in cases was highly significantly different 
that in controls (10 for cases, 9 for controls, p<2.2 x 10-16 Mann-Whitney’ test). There 
was no evidence of statistically significant interactive effects between any of the 10 
loci, compatible with each locus having an independent effect on CRC risk (p>0.05 for 
interaction, testing each locus against all others. Data not shown). 
The effects of age, gender, family history and genotype for SNPs tagging each of the 
risk loci, along with the relative weight contributed by each variable in the logistic 
regression are shown in Table 3. Because of the case-control design, the expected 
excess CRC risk for males compared to females was abrogated. However, because the 
datasets were very large (n=39,266) and case-control matching was imprecise in 
most series (due to frequency matching), there was a highly significant effect of age 
on risk. Each year of advancing age had an effect on CRC risk (Table 3B). To enhance 
power for discovery purposes, some studies had selected familial cases and/or “super-
controls” with no other affected relatives. Therefore, to assess the effect of family 
history in the logistic regression, we incorporated data from population-based studies 
where a priori selection on the basis of family history was absent (Scotland and 
DACHS), or limited (Ontario – see Table 1 legend). Odds ratios for SNP alleles at each 
risk locus are provided under an additive model. Family history of CRC, as measured 
here, imparted additional risk over and above that imparted by genotype (Table 3B) 
and so the FH and genotype provide complementary information on risk. 
The discriminative ability (probability that cases have a higher score than controls) of 
incorporating SNP genotypes at all 10 loci alone (Supplementary Fig 1A), or in 
combination with gender, age and family history data (Supplementary Fig 1B), was 
assessed by ROC. The average area under the curve (AUC) for 10 iterations in the 
cross-validation analysis was 0.57 for the model incorporating SNP genotypes alone 
(39,266 subjects), and 0.59 when incorporating genotype, age, gender and family 
history status (11,324 subjects). Values for each of the 10 iterations of cross-
validation are shown in Supplementary Table 2. Variability in discriminative ability by 
number of risk alleles incorporated into the model is shown in the Supplementary 
Figure 2, demonstrating the relationship between increasing discriminative ability with 
increasing number of risk alleles. Fitting genotype data from the external validation 
set (3067 subjects) generated an AUC of 0.56 (Supplementary Figure 3C). The 
association of the total number of risk alleles (the SCORE) was highly significant 
(P=1.2x10-6). On average each allele increased risk of CRC by 9% (OR 1.09, 95% CI 
1.05-1.13). Despite the highly significant enrichment for risk alleles in cases 
compared to controls (p = 2.2 x 10-16) and taking the results of ROC analyses 
together, it is clear that models incorporating genotype data, age, gender and FH 
 8
information have limited predictive performance across the observed risk spectrum 
and allele distributions for the individual. We estimate that the 10 common variants 
have an overall accuracy of prediction of genetic risk of only 26%. 
Next we assessed the impact on absolute risk of incorporating SNP genotypes for the 
population subgroup carrying a high number of risk alleles. Taking account of 
population allele frequency and effect size of various risk allele combinations, we 
incorporated genotype, family history, age and gender with population CRC incidence 
data. We estimated 10-year absolute risk of CRC at various ages for males and for 
females carrying at least 12 or at least 13 risk alleles. The rationale for selection of 
carriage of these numbers of risk alleles is a pragmatic one, since the frequency in the 
general population of >12 and >13 alleles is 14.1% and 5.5%, and the associated 
odds ratios at these thresholds are OR=1.58 and OR=1.71 respectively (Figure 1). We 
used Scottish population data because detailed family history data was collected 
systematically for Scottish study subjects, who themselves were sampled from the 
same population used to estimate absolute risks. We consider here that CRC risks 
calculated from Scottish population data are broadly representative of risk within 
northern European and North American populations. The risk associated with a 
positive FH in the Scottish dataset was OR = 1.75 (95% CI 1.48-2.06), marginally 
lower than estimated in a recent meta-analysis of family history as a risk factor23. The 
frequency of control subjects reporting at least one affected first-degree relative 
(0.09) in the current population is very similar to that observed in a previous Scottish 
population-based series aged 30-70 yrs (0.094. 95% CI 5.8-14.9)24. 
Using genotype data alone, or in combination with FH, the 10-year absolute risks of 
developing CRC between ages 30 and 75yrs were estimated by applying the model 
including genotype data (>12 and >13 risk alleles) and incorporating prior 
probabilities calculated from 2006 Scottish population and cancer registration data. 
Absolute 10-year risk is highly relevant in clinical practice as it is a practical timescale 
in which colonscopy can be expected to influence outcome. Absolute risks by age are 
shown for females (Figure 4a) and for males (Figure 4b). It is possible to categorise 
population groups using various level of absolute risk and here we considered 
thresholds of 5% and 10% 10-year risk for genotyped individuals.  
The estimated Scottish population aged 35-85 years in 2006 comprised 1,310,552 
males and 1,441,245 females. Using absolute risks presented in Figure 4, we 
estimated the number of males and females in the Scottish population where 
genotyping could identify those at >5% and >10% 10-year CRC risk. No males or 
females in the general population reach a 5% predicted 10-year absolute risk without 
genotype information (supplementary Table 3). The independent effect of genotype in 
the model in addition to family history should be noted (Figure 4a and 4b). Risk over 
10 years was used for the estimates for practical reasons because it is a timescale 
within which a clinical surveillance intervention could realistically be expected to 
reduce cancer risk. The predicted 10-year risk in the general population was less than 
5% for all men aged <65yrs and all women aged <70yrs, whilst only men in the age 
group 75-79yrs have >10% 10-year risk of CRC. Thus using actual Scottish 
population values, 39,211 men with >12 risk alleles of 278,091 aged 65-80 years and 
30,513 women of 216,405 aged 70-80 reach the 5% risk. Only 3,836 men with >13 
risk alleles of the 69,739 aged 75-79yrs reach a 10% threshold of 10-year absolute 
risk.  
Since a positive family history is associated with an increased risk of CRC23 and there 
is an evidence base for advancement of the age of recruitment to FOBT screening for 
FH+ individuals25, we extrapolated the findings to the Scottish population. Thus, 
genotyping the ~37,000 men aged 60-80 years with a positive family history would 
identify ~5,200 with a >5% 10-year absolute risk of CRC. Similarly, genotyping 
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~31,000 women aged 65-80 years with a family history could identify ~4,400 
reaching that risk threshold. Genotyping for common variants could thus be used to 
refine empiric guidance for people with a family history of CRC, as well as providing 
additional information on risk, over and above FH.  
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Discussion 
We set out to assess the potential utility of genetic risk profiling for CRC in the general 
population. We used genotype information at 10 loci known to be associated with CRC 
susceptibility. Whilst the discriminative ability of any of the models was limited across 
the risk spectrum, we show that combining genotype data with gender, age and 
family history information (as a proxy for genetic susceptibility factors yet to be 
discovered) can identify individuals with a substantially raised 10-year absolute risk of 
CRC. We propose that the risk level is sufficiently high for those with at least 12 
alleles in specific age groups that additional screening measures are warranted, such 
as colonoscopic surveillance and/or age advancement of recruitment to population 
FOBT screening programmes.  
This study of 8 different populations of European origin comprised analysis of data 
from 42,333 subjects genotyped for all 10 genetic risk loci so far identified. In addition 
to the expected association with a positive family history and increasing age, there 
was a highly significant difference between cases and controls in the mean, and 
median, number of risk alleles at the 10 CRC susceptibility loci (p<2.2 x 10-16).  We 
generated models to combine genotype information at each of the 10 loci associated 
with CRC, age, gender and family history variables, but we found limited 
discriminative ability to differentiate cases from controls (AUC ~0.59 and 0.57 
(internal validation) or 0.56 (external validation set) from ROC curve analysis of 
models including or excluding FH information) and an overall positive predictive value 
between 0.51 and 0.71 for cut-off points of 0.4 and 0.7 respectively, The negative 
predictive value for the same cut-offs ranged between 0.62 and 0.51. This modest 
level of test performance was consistent across study populations in the internal and 
external validation steps. This suggests that risk assessment algorithms based on 
common genetic variants will have similar performance characteristics in Caucasian 
populations and are unlikely to be confounded by population differences, since the 
study populations all have very similar LD structure. 
Despite the large dataset studied here, we found that common genetic variants 
associated with CRC which have been identified to date cannot be used alone or in 
combination with each other and age, gender and family history for individualized 
profiling across the risk spectrum in the general population. This is consistent with the 
recent risk prediction studies in other diseases which have been disappointing to 
date26-28. Typical AUCs have ranged from 0.55 to 0.60 in type 2 diabetes29-32 to 
slightly higher values for age-related macular degeneration (AMD), Crohn's Disease, 
coronary heart disease and cardiovascular diseases33-35. The best predictive 
performances have been obtained by combining genetic, demographic, and 
environmental variables as for AMD36. An important issue is that the great majority of 
true susceptibility loci are not been included in these analyses because they have yet 
to be discovered. The four published prediction models for type 2 diabetes studied 
around 20 SNPs and this is typical of these studies. A substantially improved 
predictive performance (AUC > 0.8] can be achieved by including SNPs from a much 
larger number of susceptibility loci35. Consistent with this, we have estimated that a 
model with approximately 100 SNPs of the estimated 172 loci accounting for all the 
genetic variance for CRC could provide an 80% accuracy of prediction, and explain 
~17% of the phenotypic variance in the liability scale37.  
Although accurate individual risk assessment is not currently possible, the findings 
presented here suggest that it is possible to partition population subgroups by 
absolute risk thresholds. Furthermore, we show that the number of people in this high 
risk subgroup is manageable, indicating that genotyping could be feasible. The use of 
a threshold of a 5% absolute 10-year risk of CRC has clinical and public health 
validity. The 5% risk exceeds the highest risk achieved throughout life in males or 
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females and is ten times greater than the risk of a 50-year old entering the 
population-based FOBT screening in the populations studied here. 
ROC analysis indicates modest discriminative ability for any of the predictive models 
studied here. However, AUC represents the probability that cases have a higher score 
than controls. Whilst this is important for a diagnostic test, it only gives a limited 
assessment of a predictive test where the main aim is categorisation into clinically 
meaningful risk strata28. AUC does not address absolute levels of risk or whether the 
model stratifies correctly into high/low categories of absolute risk which are of clinical 
importance (eg 10-year risk of CRC). Prediction of actual risk is a more important 
function of the model than the sensitivity/specificity (on which the ROC curve and AUC 
estimate are based). 
It is likely that the combined performance of genetic variants and other established 
(non-genetic) risk may vary depending on the nature of the genetic variants 
incorporated into the model28. It would be expected that these will have a greater 
impact if they are involved in novel disease pathways which are independent from the 
causal mechanisms through which the other risk factors operate27– as is likely in this 
study in which many of the variants are involved in the TGB beta signalling pathway37. 
This study explored model performance across a range of European populations in 
order to reduce potential bias due to limited representativeness of study data for the 
settings in which the genetic testing will be applied. Although we validated these 
findings in an external validation set, model performance should be tested in a large, 
long-term cohort study in which the genetic variants can be studied together with 
classical risk factors to give reassurance that model performance is not inflated due to 
selection, information or survival biases. 
The findings presented here have implications for the current CRC FOB screening 
programmes. Brenner has argued that the “risk advancement” associated with a 
positive family history should logically dictate that these individuals should enter the 
screening programme about 10 years earlier that those with a negative family history 
(based on equivalent 10 year risks of CRC and assuming equal programme 
effectiveness in these two groups)25. 
With current intense research activity, it is likely that additional common genetic 
variants associated with CRC risk will be identified. Because the effect sizes are likely 
to be small and/or the allele frequencies may be lower than those identified to date. 
Nonetheless, predictive utility of testing for common genetic variants is likely to 
improve with new discoveries and individualized genetic risk profiling for CRC may 
become a reality in the foreseeable distant future. Furthermore, performance should 
improve further when the causal variants at these loci are discovered through fine 
mapping and functional studies. 
Whilst there are a number of issues that need to be addressed in order to translate 
any genetic test into clinical and public health practice, we have shown, in principle, 
that it is already possible to identify a proportion of the population at substantially 
increased risk of CRC. These individuals have sufficiently high risk to merit individual 
intensive surveillance.  Furthermore, amendments to criteria for age of entry to family 
history focussed surveillance programmes5,38 should be considered and evaluated. 
This study provides tangible evidence that data from genome-wide studies of CRC 
have public health and clinical relevance. 
Table 1:  Description of study type with category of case/control subjects genotyped 
*Although the majority of recruited cases were low risk, there was some enrichment of OFCR cases for FH+ since all index cases who came from high and 
intermediate risk families were included39.  All OFCR controls were unselected with respect to FH. 
 
  Cases Controls Study type Source of controls Case or control 
selection by FH 
FH data available for 
case and controls 
Cambridge (SEARCH) Male 1277 949 
 Female 941 1313 
 Total 2218 2262 
Population-based 
Population - frequency 
matched age/gender 
NO NO 
Ontario (OFCR) Male 514 673 
 Female 676 524 
 Total 1191 1197 
Population-based 
Population - frequency 
matched age/gender 
Some case 
selection* 
YES 
Colon CFR Male 463 215 
(excludes Ontario Female 442 300 
 Subjects) Total 905 515 
Population-based 
Population - frequency 
matched age/gender 
YES. FH-ve super-
controls 
YES 
Heidelberg (DACHS) Male 789 719 
 Female 582 760 
 Total 1371 1479 
Population-based 
Frequency matched by 
age/gender/county of 
residence 
NO YES 
Epicolon1 Male 649 249 
 Female 447 196 
 Total 1096 445 
Population-based 
Frequency matched 
age/gender 
YES. FH-ve super-
controls  
YES 
Epicolon2 Male 573 320 
 Female 339 229 
 Total 912 549 
Population-based 
Frequency matched 
age/gender 
YES. FH-ve super-
controls 
YES 
Kiel/Greifswald Male 1089 1059 
 Female 1080 1086 
 Total 2169 2145 
Population-based 
Population - frequency 
matched age/gender 
YES. FH-ve super-
controls 
YES 
London (CORGI) Male 275 419 
 Female 335 507 
 Total 610 926 
Population-based 
Clinical genetics 
centres 
Cancer-free spouses of 
cases 
YES. FH+ve 
enriched cases 
YES 
London (NSCCG) Male 1159 1094 
 Female 1636 1605 
 Total 2795 2699 
Population-based 
Oncology clinics  
Cancer-free 
spouses/friends of cases 
NO NO 
London (NSCCG) Male 4560 1246 
 Female 2363 2103 
 Total 6925 3352 
Population-based 
Oncology clinics 
Cancer-free 
spouses/friends of cases 
NO NO 
Scotland (COGS) Male 498 514 
 Female 482 488 
Population-based 
 
Matched age/gender, area 
of residence 
NO YES 
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 Total 980 1002 
Scotland (SOCCS) Male 1222 1230 
 Female 802 862 
 Total 2024 2092 
Population-based 
 
Matched age/gender, area 
of residence 
NO YES 
VICTOR Male 764 628 
 Female 438 706 
 Total 1202 1334 
Cases recruited to 
RCT 
WTCCC 1958 Birth Cohort 
and cancer-free spouse 
controls, and European 
Cell Culture Collection 
random human control 
DNA samples. 
NO NO 
Total subjects used for  Male 13832 9315 
model generation and  Female 10563 10679 
internal validation Total 24395 19994 
    
External validation 
(Sweden) 
Total 1,777 1,751 Population-based 
Cancer-free blood donor 
and spouse controls 
NO NO 
Total study subjects Total 26,172 21,745 (47,917) 
14 
 
 
Table 2: Population-based studies with family history information.  
 
 FH Controls Cases 
Ontario (OFCR) No 1039 879 
 Yes 155 310 
DACHS No 1313 1187 
 Yes 163 180 
Scotland COGS No 936 861 
 Yes 66 119 
Scotland SOCCS No 1881 1709 
 Yes 211 315 
Total No 5169 4636 
 Yes 595 924 
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Table 3.  
A. Results of logistic regression to assess the effect of genotype at each of the 10 risk 
loci for samples with genotypes at all 10 SNPs. B. Effect of genotype, age, gender and 
family history for study populations where study design did not involve case or control 
selection on the basis of FH criteria (see Table 2).    
 
 Estimate SE Pr(>|z|) OR Upper 95%CI Lower 95%CI 
A.  Study populations with SNP genotype data for all ten risk loci (n=39,266) 
rs10411210 0.12 0.02 2.07x10-6 1.13 1.18 1.07 
rs9929218 0.11 0.02 1.60x10-11 1.11 1.15 1.08 
rs6983267 0.17 0.01 < 2 x10-16 1.19 1.22 1.15 
rs4779584 0.13 0.02 6.86 x10-14 1.14 1.18 1.10 
rs4939827 0.19 0.01 < 2 x10-16 1.21 1.25 1.18 
rs3802842 0.13 0.02 < 2 x10-16 1.14 1.18 1.11 
rs10795668 0.11 0.02 6.53 x10-13 1.12 1.15 1.09 
rs16892766 0.20 0.03 3.32 x10-15 1.23 1.29 1.16 
rs961253 0.10 0.02 4.68 x10-12 1.11 1.14 1.08 
rs4444235 0.09 0.01 2.77 x10-9 1.09 1.12 1.06 
       
B. Study populations with genotypes for all ten risk loci. Not selected for FH (n=11,324) 
Age -0.01 0.00 4.16 x10-5 0.99 1.00 0.99 
Gender M>F 0.00 0.04 0.97 1.00 1.08 0.93 
FH 0.51 0.06 < 2 x10-16 1.66 1.87 1.48 
rs10411210 0.16 0.05 1.26 x10-3 1.17 1.29 1.06 
rs9929218 0.13 0.03 3.16 x10-5 1.14 1.21 1.07 
rs6983267 0.16 0.03 3.77 x10-8 1.17 1.24 1.11 
rs4779584 0.15 0.03 2.35 x10-5 1.16 1.24 1.08 
rs4939827 0.18 0.03 4.39 x10-10 1.19 1.26 1.13 
rs3802842 0.19 0.03 1.89 x10-10 1.21 1.29 1.14 
rs10795668 0.06 0.03 0.057 1.06 1.12 1.00 
rs16892766 0.24 0.05 7.41 x10-7 1.27 1.40 1.16 
rs961253 0.15 0.03 6.35 x10-7 1.16 1.23 1.09 
rs4444235 0.09 0.03 2.34 x10-3 1.09 1.15 1.03 
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Figure 1  Odds ratios (95% CI) for each specific number of risk alleles are shown by 
diamonds, using 9 alleles as the reference (A). Odds ratios (95% CI) for thresholds of 
risk alleles are indicated by squares (thus risk associated with carrying 10 alleles and 
more is compared to 9 alleles and less, and so on). Allele frequency distribution in 
cases and controls from all populations used in generating the models is shown in 
columns. Data are shown in tabular form (B) for odds ratios for number of risk alleles 
and partitioned by various thresholds of risk alleles. 
 
A 
 
 
B 
Risk alleles ≤4 5 6 7 8 9 10 11 12 13 ≥14 
Cases 45 200 573 1485 2825 3973 4247 3848 2484 1276 686 
Controls 90 309 833 1655 2832 3515 3353 2557 1507 665 308 
Number of alleles ≤4 5 6 7 8 9 10 11 12 13 ≥14 
Odds ratio 0.44 0.57 0.61 0.79 0.88 1.00 1.12 1.33 1.46 1.70 1.97 
Lower 95% CI 0.30 0.47 0.54 0.73 0.82 - 1.05 1.24 1.35 1.53 1.71 
Upper 95% CI 0.64 0.69 0.68 0.86 0.95  1.20 1.43 1.58 1.89 2.28 
Threshold ≤4 ≤5 ≤6 ≤7 ≤8 ≥9 ≥10 ≥11 ≥12 ≥13 ≥14 
Odds ratio 0.41 0.49 0.52 0.61 0.65 1.55 1.52 1.55 1.58 1.71 1.84 
Lower95% CI 0.28 0.42 0.48 0.52 0.62 1.48 1.48 1.49 1.50 1.57 1.60 
Upper 95% CI 0.59 0.55 0.57 0.64 0.68 1.62 1.58 1.62 1.67 1.85 2.11 
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Figure 2:  Box plot of number of risk alleles in case and control subjects for each 
study population used in the generation and internal validation of the risk models (A) 
and in the external validation (B). Median number of risk alleles for cases and controls 
combined is indicated by a heavy black line. Mean number of alleles in cases by fine 
solid grey line and broken grey line for controls. There was a marginal difference in 
median number of risk alleles (9 versus 10) in DACHs compared to other populations, 
but the difference in mean number of alleles between cases and controls was similar 
to that in all other populations. 
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Figure 4 
Absolute 10-year risk of CRC for cancer-free females (A) and males (B) within the general 
population carrying >12 or >13 risk alleles. (Note scale difference in absolute risk between 
female and male graphs). 
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Supplementary Table 1 
 
Odds ratio (95% CI) estimated by logistic regression by number of risk alleles with 
reference to 9 alleles as the median number of risk alleles in the study populations. 
 Estimate SE z value Pr(>|z|) OR 
Upper_95% 
CI 
Lower_95% 
CI 
(Intercept) 0.12 0.02 5.29 1.23x10-7 1.13 1.18 1.08 
≤4 -0.82 0.18 -4.43 9.34x10-6 0.44 0.63 0.31 
5 -0.56 0.09 -5.95 2.64x10-9 0.57 0.69 0.48 
6 -0.50 0.06 -8.42 <2x10-16 0.61 0.68 0.54 
7 -0.23 0.04 -5.42 5.93x10-8 0.79 0.86 0.73 
8 -0.12 0.04 -3.54 3.94x10-4 0.88 0.95 0.82 
10 0.11 0.03 3.48 4.99x10-4 1.12 1.19 1.05 
11 0.29 0.03 8.31 <2x10-16 1.33 1.42 1.24 
12 0.38 0.04 9.43 <2x10-16 1.46 1.58 1.35 
13 0.53 0.05 9.96 <2x10-16 1.70 1.88 1.53 
≥14 0.68 0.07 9.37 <2x10-16 1.97 2.27 1.71 
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Supplementary Table 2.  
Results of 10 successive iterations of validation in those subjects with age, sex and 
genotype data who were not selected in any way by FH criteria and in subjects all 
subjects with genotype data at every SNP.  
 
Iteration Age, sex, FH,     
10 genotypes 
(11,324 subjects) 
10 genotypes alone    
(39,266 subjects) 
  AUC 
1 0.61 0.57 
2 0.59 0.57 
3 0.60 0.58 
4 0.61 0.58 
5 0.62 0.59 
6 0.59 0.57 
7 0.56 0.57 
8 0.60 0.58 
9 0.58 0.57 
10 0.58 0.57 
Mean 0.59 0.57 
 
Supplementary Table 3 
Scottish population data and incidence rates, along with cumulative probably of developing CRC by age and gender. 10-year risk 
associated with carriage of 12 or more and 13 or more alleles in those with a family history of CRC and irrespective of FH. 
 
Age group 0-29 30 35 40 45 50 55 60 65 70 75 
Scottish population            
Males in age group 653725 153686 185147 194867 183306 164736 169377 135028 113650 94702 69739 
Population 10-yr risk - male 0.000 0.000 0.001 0.002 0.004 0.007 0.012 0.020 0.029 0.040 0.046 
Cumulative probability of CRC-male  0.01%  0.05%  0.26%  0.94% 1.72% 2.90% 4.66% 
   
Females in age group 632555 163497 199628 210261 194619 170649 175422 144542 129719 117673 98732 
Population 10-yr risk - female  0.000 0.001 0.002 0.003 0.005 0.008 0.013 0.017 0.022 0.029 
Cumulative probability of CRC-female  0.02%  0.06%  0.25%  0.76% 1.21% 2.05% 2.95% 
            
10-yr risks FH+            
Male >=12 alleles, 10-yr risk 0.000 0.001 0.001 0.003 0.006 0.012 0.024 0.044 0.076 0.124 0.187 
Female >=12 alleles, 10-yr risk 0.001 0.001 0.002 0.003 0.006 0.012 0.019 0.031 0.053 0.077 0.113 
            
Male >=13 alleles, 10-yr risk 0.000 0.001 0.002 0.003 0.008 0.015 0.029 0.054 0.093 0.152 0.230 
Female >=13 alleles, 10-yr risk 0.001 0.001 0.002 0.004 0.008 0.014 0.024 0.038 0.065 0.095 0.139 
            
10-yr risks irrespective of FH status           
Male >=12 alleles, 10-yr risk 0.000 0.001 0.001 0.002 0.004 0.008 0.016 0.029 0.049 0.080 0.121 
Female >=12 alleles, 10-yr risk 0.000 0.000 0.001 0.002 0.004 0.008 0.013 0.020 0.034 0.050 0.073 
            
Male >=13 alleles, 10-yr risk 0.000 0.001 0.001 0.002 0.005 0.009 0.017 0.032 0.054 0.089 0.134 
Female >=13 alleles, 10-yr risk 0.000 0.001 0.001 0.002 0.005 0.008 0.014 0.022 0.038 0.055 0.081 
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ROC curves assessing the discriminative ability of a model incorporating only genotype data for the 10 risk SNPs (A) (39,266 
subjects) and of a model incorporating genotype data for the 10 SNPs along with age, FH status and gender (B) (11,324 subjects). 
Mean ROC is plotted and the spread of the estimates shown as a box-plot along the ROC curve is shown for A and B. External 
validation comprised analysis of genotype data from 3,067 subjects (C).  
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Supplementary Figure 1 
 
 
 
Supplementary Figure 2 
Variation in predicted probability of CRC (n=39,266) for a given number of risk alleles 
in the model incorporating genotype data. 
 
R2=0.59 
y=0.25+0.03x 
 
Coefficients 
  Estimate SE t value Pr(>|t|) 
Intercept 0.2541780   0.0013387    189.9 <2x10-16 
Total 0.0320488   0.0001354    236.6    <2x10-16 
         
Significance codes:  0 ‘***’ 0.001 ‘**’ 0.01 ‘*’ 0.05 ‘.’ 0.1 ‘ ’ 1  
 
Residuals 
Min         -0.137199 
1Q           -0.047355  
Median     0.007621  
3Q            0.046141  
Max          0.125501 
 
 
 
 
 
 
Residual standard error: 0.05236 on 38,320 degrees of freedom   (6073 observations 
deleted due to missing values). Multiple R-squared: 0.5937,   adjusted R-squared: 
0.5937. F-statistic: 5.599x104 on 1 and 38,320 DF, p-value: < 2.2x10-16 
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